Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from breaking when cells copy damaged genetic material, a discovery that could ...

In oncogenetics, some patients could be considered as "extreme phenotypes," such as those with very early onset presentation or multiple primary malignancies, unusually high numbers of cancers of the ...

Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell lung cancer (SCLC). Their study, published in Science Advances and titled ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia ...

Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study. Background: Small cell lung cancer ...

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors. Background: Ceralasertib (AZD6738) is a selective ...

MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestones BRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- ...

Shanghai Annova Biotechnology Co. Ltd. has disclosed substituted fused heterocyclic compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer.

Please provide your email address to receive an email when new articles are posted on . ATR-04 has received a fast track designation from the FDA for epidermal growth factor receptor ...

ROCKLAND, Mass.--(BUSINESS WIRE)--Not intended for UK-based media EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced key clinical ...